tively to prevent graft rejection. Our identification of patients who developed severe generalized weakness after orthotopic liver transplantation8 (OLTx) prompted a prospective investigation to identify both the frequency of myopathy as a cause of generalized weakness and potential risk factors for myopathy in the liver transplant population.
Methods. Patient selection. Beginning in August 1995, 100 consecutive adult patients undergoing OLTx at the University of Pittsburgh Medical Center were evaluated prospectively. Because many patients with liver failure have mild generalized weakness, our goal was to identify patients with clinically significant weakness of neuromuscular origin that affected the lengths of hospitalization or intensive care treatment. Therefore, all patients who were hospitalized greater than 14 days or who remained mechanically ventilated more than 7 days after OLTx underwent a detailed neuromuscular evaluation by one examiner (J.V.C.). Patients who could not be fully assessed or hemodynamic instability were reexamined when their condition permitted accurate assessment of neuromuscular weakness. Patient interview, admission examination as recorded by the transplant service, and, when applicable, outpatient records were reviewed in all patients for any preexisting neurologic diseases. Preoperative neurologic assessment was not feasible, because the time of liver transplantation is rarely predictable and because many patients are encephalopathic before transplantation.
Pharinacologic therapies. Intraoperatively, patients received 1 gram of IV methylprednisolone (MP) followed by tapered boluses until the fifth postoperative day (total, 1,600 to 1,700 mg MP) when prednisone 20 mglday was given orally. Additional IV MP boluses used for treatment of graft rejection or during retransplantation were noted. Tacrolimus (FK-506) was initiated during OLTx via continuous IV infusion at a rate of 0.075 mgkglday and continued until oral administration was possible. The dosage of tacrolimus was titrated based on daily measurements of its whole blood concentration to achieve a level between 10 and 20 ng1mL. One patient received cyclosporin-A instead of tacrolimus. The type(s) and dosage of NMBA used was at the discretion of the transplant team. Generally, NMBA administration was limited to the intraoperative period, although some patients received NMBAs via intermittent dosing with "train of four" monitoring in the postoperative period. Postoperatively, patients routinely had daily assessments of bilirubin, liver enzymes, CBC, electrolytes, BUN, creatinine, and tacrolimus levels until they were discharged from the ICU. Serum glucose was monitored at least daily and as frequently as hourly in patients requiring insulin infusions. Operative and daily medication records were reviewed for the types and quantities of immunosuppressants and NMBAs administered. Systemic complications and laboratory tests were carefully assessed. Patients with significant weakness (Medical Research Council score 3 or less in at least one muscle group) and without an apparent CNS etiology were further evaluated only after written informed consent for measurement of serum CK, electrodiagnostic testing, and muscle biopsy was obtained from the patient or their designated representative. This protocol was approved by the Institutional Review Board at the University of Pittsburgh Medical Center.
Neurodiagnostic and histopathologic evaluations. Nerve conduction studies (NCS) and concentric needle EMG were performed by routine methodssJ2 using supramaximal percutaneous stimulation and surface recording electrodes. At least radial and sural or superficial peroneal sensory responses and median or ulnar and tibial or peroneal motor responses were evaluated on all patients. Repetitive stimulation of motor nerves was performed with supramaximal stimulation at a frequency of 3 and 30 Hz at baseline and at 3 Hz after exercise (or after 30-Hz stimulation if the patient was unable to exercise).
Patients with suspected myopathy underwent either open surgical biopsy (vastus lateralis, Patient 3) or percutaneous needle muscle biopsy (deltoid, all other patients) in the fashion described by Cote et al. 13 Cryostat sections (8 pm) were stained with hematoxylin and eosin (H-E),
Assessment of potential risk factors.
Gomori trichrome, NADH-TR, ATPase (pH 4.3, 4.6, and 9.41, oil red-0, and PAS. Paraffin sections were stained with H-E. The percentage of acutely necrotic myofibers was assessed on H-E and Gomori trichrome stained cryostat sections and H-E stained paraffin sections. Electron microscopy was performed by routine methods.
Muscle (psoas) was also obtained at autopsy from four patients who died within 1 month after OLTx to assess for subclinical myopathic changes. Specimens were embedded in paraffin and stained with H-E.
For the purpose of analyzing potential risk factors for the development of weakness, clinical and laboratory features of patients with myopathy were compared with those of patients who did not develop persistent, debilitating, generalized weakness after OLTx (control subjects). Patients excluded from analysis were those who remained hospitalized greater than 14 days but did not have a neurologic examination (3 patients) and those who died before being examined (10 patients).
Determination of the significance of differences between groups in the frequency of discrete variables was made using the chi-square test. These factors included the frequency of diabetes mellitus (not controlled by diet alone) or significant alcoholism (clinical history with consistent native liver pathology) before transplantation and the development of renal insufficiency requiring dialysis within a 10-day postoperative period.
The Wilcoxon rank-sum test was performed on sets of continuous data. Parameters included the amount of glucocorticoids received, measurements of serum glucose (mean of daily peaks), and whole blood tacrolimus levels (peak and mean) during the 7-day postoperative period. Acute physiology and chronic health evaluation (APACHE-11) scores14 (postoperative day 1) and serum bilirubin (postoperative day 7) were analyzed similarly. Glucocorticoid doses are expressed in mg MP. If patients required multiple transplantations during the same hospitalization, total glucocorticoid doses include those received during the initial procedure until 7 days after the final procedure. Multivariate analysis via logistic regression was also performed to determine whether there was an independent difference in APACHE-I1 scores, glucose levels, and MP doses between the myopathy group and control subjects.
Statistical significance is considered as p < 0.05.
Results.
One hundred patients (59 male and 41 female aged 17 to 73 years, mean, 53 years) underwent 110 OLTxs during the 7-month study. Indications for OLTx are listed in table 1. One patient underwent combined heartliver transplant, and two patients received combined kidney-liver transplants.
Of these 100 patients, a full neurologic examination was not performed on 23. Ten expired during the immediate postoperative period from nonneurologic complications, and an accurate assessment of muscular weakness was not possible. Ten had expedient unremarkable recoveries and were ambulatory upon discharge from the hospital by day 14 and did not meet our criteria for neurologic examination. One patient refused examination and two were inadvertently excluded from assessment. All surviving patients who were not examined underwent review of their hospital course and follow-up outpatient evaluations. None reported a new neurologic disability. Although we cannot i Acute hepatic artery thrombosis resulted from postoperative arterial occlusion (typically a dissection) or from a low flow state.
exclude mild weakness in the surviving patients that we did not personally evaluate, these patients clearly did not have functional disability. In the remaining 77 patients, severe quadriparesis was identified in 8 patients in the immediate postoperative period. One patient experienced significant rapid improvement in strength within 2 days. Further evaluation was not pursued, and the cause of the transient weakness was not determined. Seven patients (table 2) had significant weakness that persisted longer than 2 weeks. All seven patients with prolonged weakness had medical complications in the postoperative period preceding or associated with the onset of weakness, including infection, renal failure, or liver graft failure. Six of these seven patients demonstrated greatly diminished tone and tendon reflexes at the time of maximal weakness. All had moderate facial paresis. Weakness was most pronounced proximally and included significant involvement of neck flexors. Distal muscles were affected minimally in three patients and extraocular motility was spared except in Patient 2. Sensation was normal except for mild loss of distal proprioception and vibratory perception in two patients. Serum CK measurements are reported in table 2.
Patient 5 withdrew consent to participate in the study before electrodiagnostic study and muscle biopsy. In the remaining six patients with prolonged weakness, needle EMG and NCS were performed between postoperative days 11 and 41 and on postoperative day 67 in Patient 2.
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The EMG was delayed in Patient 2 because weakness was not ascertained until a multifactorial encephalopathy cleared, although profound hyporeflexia was present by postoperative day 13. Sensory nerve conductions were normal or demonstrated only minimal abnormalities such as absent sural nerve sensory responses (three patients) or minimally reduced sensory amplitudes or conduction velocities (CV) (75 to 99% of the lower limit of normal in agematched control subjects) in other nerves. Compound muscle action potential (CMAP) amplitudes were substantially low (<50% of the lower limit of age-matched normal subjects) in multiple nerves in six patients. One patient with proximal weakness demonstrated only minimally decreased CMAP amplitudes in two distal muscles. Except for common sites of nerve entrapment, motor nerves demonstrated normal CV and showed no evidence of conduction block or focal slowing. Repetitive stimulation was not performed in two patients who were evaluated more than 4 weeks after onset of weakness; one other patient was intolerant of this testing. There were no decremental or incremental responses in CMAP amplitude in the remaining three patients. Needle EMG revealed increased insertional activity with diffuse fibrillation potential and positive sharp wave activity in all patients. The abnormal spontaneous activity was prominent in all patients except Patient 2. Motor unit potentials (MUPs) were low in amplitude, short in duration, and often polyphasic with an early recruitment pattern. These MUP abnormalities were generally diffuse but were more prominent in proximal muscles. Electrical myotonia was quite prominent in the proximal musculature of Patient 7. Percussion myotonia could not be elicited in this patient, and electrodiagnostic and clinical follow-up are not available because he died.
Muscle histopathology in five patients revealed scattered atrophic angulated fibers (type I1 more than type I) that often exhibited basophilic stippling with the H-E stain. There was particularly severe type I1 fiber atrophy in the specimens from Patients 1 and 6. All had variable amounts of acute necrosis affecting from 5% (Patient 4) to 50% (Patient 7 ) of myofibers, and the necrosis was extremely patchy in Patient 7. Myophagocytosis (macrophage infiltration of necrotic fibers) was uncommonly seen in four specimens and was absent from Patient 6's specimen. Disruption of the intermyofibrillar network and small dark angulated fibers were observed in NADH-TR reacted specimens, and there was decreased or absent reactivity for myosin-ATPase at all pHs in 5 to 50% of nonnecrotic fibers in all five specimens (figure). The specimens from Patients 4 and 7 exhibited the greatest myosin loss. Congo-red staining was negative for amyloid in the patient with amyloidosis (Patient 7).
All five patients with myopathy who had muscle biopsies had ultrastructural findings of myofibers with selective loss of thick filaments. Both nonatrophic and especially atrophic fibers were affected. Additional findings included scattered necrotic and normal fibers, nonspecific disruptions of myofilaments, linear aggregates of normal mitochondria, and focal accumulations of free glycogen, lipid, and lipofuscin. Minimal alterations in sarcotubular elements were noted.
The results of our analysis of variables associated with development of myopathy are summarized in table 3.
During the postoperative period, three patients with 14) . Autopsy muscle serving as histopathologic control subjects w a s obtained from four patients who died within 1 month of OLTx to assess subclinical myopathic changes. One patient w a s ambulatory on the d a y of death. Significant muscle weakness could not be completely excluded in the other three patients because of severe medical complications and limited neurologic examinations. One control specimen exhibited m a n y atrophic angulated fibers and rare regenerating fibers. Other specimens lacked muscle necrosis a n d myophagocytosis a n d degeneration or regeneration.
Discussion. The epidemiology of CNS complications after liver transplantation is well d o c~m e n t e d , l~-~~ but the frequency and features of neuromuscular disorders in this patient population have not been prospectively determined. A retrospective study of OLTx patients disclosed that about 1% developed significant weakness due to myopathy. 20 The cause of myopathy was uncertain, but features were consistent with those reported in other critically ill patients. Our clinical, electrodiagnostic, and histopathologic findings revealed an acute myopathy was a cause of severe prolonged weakness in at least six patients (6%) in this series. One other patient had prolonged proximal weakness, likely of myopathic origin, but he refused further evaluation.
We did not identify other neuromuscular causes of generalized weakness in our patients. However, liver transplant recipients are critically ill and at risk for developing weakness from a variety of neuromuscular d i s e a~e s .~~-~~ Critical illness polyneuropathy (CIP), an acute axonal sensorimotor neuropathy, occurs in patients with sepsis and multiorgan failure, usually after 1 to 2 weeks of intensive care hospitali z a t i~n .~~,~~ We did not identify any patients with a substantial acute axonal sensorimotor polyneuropathy consistent with CIP, but our study evaluated acute weakness occurring usually within 2 weeks after OLTx.
Weakness from persistent neuromuscular blockade has also been well described in occasional patients who receive high doses of Delayed clearance of these drugs or their active metabolites is believed to contribute to this complicat i~n , l l .~~ which usually occurs after prolonged paralysis from large amounts of NMBAs. Weakness usually resolves within a few days and typically lasts less than 1 week.11.21, 27 We cannot exclude persistent neuromuscular blockade as a cause of weakness in the single patient with short-lived weakness. Prolonged neuromuscular junction blockade is unlikely to be responsible for weakness in the patients with prolonged symptoms because of the electrophysiologic and histopathologic findings in addition to the length of the recovery period.
Features of acute myopathy. The clinical features of our patients with myopathy are nonspecific but consistent with an acute, usually reversible, myopathy that occurs in other critically ill patients. Patients develop flaccid paralysis, commonly involving the face, diaphragm, and occasionally the extraocular muscles.l-ll Many received NMBAs, high doses of corticosteroids, or both. The CK may be elevated, but identification of the elevation may depend on the timing of the sampling.8 Although half of our patients had elevated CK measurements, spurious elevations may be a result of the extensive surgical procedure, and we did not directly compare CK measurements in patients with myopathy to control subjects because of this confounding variable.
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Figure. Serial cryostat sections from the needle biopsy specimen from Patient 7 are shown, (A) Gomori tricfirome stained section reveals a variation i n myofiber sizes with atrophic fibers and occasional necrotic fibers (arrowheads). Myosin-ATPase reacted sections at p H 4.6 (B) and p H 9.4 (C) reveal many nonnecrotic fibers with reduced or patchy staining at both pHs (see arrows for examples). Bar
Regarding electrodiagnostic features, a mild neuropathic accompaniment was noted in previously described p a t i e r i t~~~~,~ and cannot be entirely excluded in all our patients. The patients we studied had a variety of chronic illnesses associated with neuropathy, but the clinical features and pathologic findings show that a myopathic process was the predominant cause of weakness. Additionally, minor sensory nerve conduction abnormalities in our patients likely represented the technical limitations of performing electrophysiologic studies in the ICU on patients who frequently were edematous. In Patient 7, we noted electrical myotonia, which supports the contention of Rich et a1.,l0 that there may be an alteration of muscle membrane function.
Our muscle histopathologic findings were within the spectrum of changes reported in other critically ill patients.2.5-8~29~30 Although not universally noted, a common feature of this disorder is the selective loss of myosin thick filament^^,^,^ that we observed in all our patients with myopathy who underwent muscle biopsy. The myopathy with loss of thick filaments is unlikely to be related t o liver disease alone, because similar pathologic changes have been noted in patients with other critical illnesses associated with normal liver f u n~t i o n .~,~.~ In addition, our autopsy control muscles lacked significant histopathologic evidence of myonecrosis (based on paraffin sections). Although our patients with acute myopathy usually had myopathic changes in paraffin-embedded sections, our autopsy control data do not exclude the possibility of more subtle myopathic changes and myosin loss, which are only seen in frozen sections.
Risk factors for myopathy in liver transplant patients. The mechanism by which critically ill patients acquire myopathy is not understood. A theory supported by animal models suggests that denervation in addition to high-dose IV-CS leads to selective loss of myosin thick filament^.^^,^^ Our patients received relatively low doses of NMBAs compared with the amounts reported in many ventilated asthma patients with acute m y~p a t h y .~,~,~ Because many of our OLTx patients received more than one type of NMBA (as many as four), we found comparing doses of NMBAs between myopathic patients and control subjects to be impractical. However, the doses did not vary greatly between the two groups and myopathy occurred after exposure t o a wide range of cumulative doses. Several NMBAs, especially vecuronium and to a lesser degree pancuronium, are hepatically metabolized and are renally excreted along with their active metabolite^.^^.^^,^^ The increased frequency of dialysis requirement in our patients with myopathy supports renal failure as a risk factor for developing myopathy, possibly due to prolonged NMBA exposure. In addition, all our patients initially had hepatic insufficiency, but we did not find a difference in postoperative liver function (bilirubin measurement at postoperative day 7) between groups. However, patients with graft dysfunction who required a repeat transplant frequently developed myopathy (or died). Such patients were transiently anhepatic, also suggesting prolonged NMBA exposure due to failure of drug metabolism contributed to the development of myopathy in our patients. Our findings support previously reported associations between IV-CS dosage and development of acute myopathy in critically ill patients. 34 Generally, patients in our study received higher doses of IV-CS in the presence of graft rejection or other liver disorders that required retransplantation. However, multivariate analysis revealed CS dosage was a risk for myopathy independent of illness severity.
Other drugs may cause myopathy in liver transplant patients. Cyclosporin-A and the related immunosuppressant, tacrolimus, share common CNS side effect^.^^,^^ We compared both peak tacrolimus levels and mean levels during the first postoperative weak (an indicator of cumulative dose) to determine if myopathy may occur as a result of an acute toxic event or from cumulative tacrolimus toxicity. Although cyclosporin has previously been associated with myopathy,37,38 we did not note a relationship between either mean or peak blood levels of tacrolimus and a risk of developing myopathy. Because myopathy was less frequent in another liver transplant population that received either tacrolimus or cyclosporin,20 it is possible that the higher frequency we observed may be a side effect of tacrolimus that is dose independent. Likewise, this could be due t o more detailed neurologic screening in our population. Therefore, a comparison of myopathy frequency in cyclosporintreated patients versus tacrolimus-treated patients is an issue warranting further study.
Regarding metabolic disturbances, hyperglycemia may have a harmful effect on the nerve microenvir~n m e n t~~ and is associated with CIP.40 Because denervation in conjunction with IV-CS may lead to depletion of myosin thick filament^,^^,^^ further alteration of the motor axon by hyperglycemia might increase the likelihood of developing myopathy.
Although more severe in the group of patients with myopathy, hyperglycemia during the postoperative period was determined not to be an independent risk through multivariate analysis and may simply be another indicator of illness severity or may be secondary to larger doses of IV-CS.
In addition to evaluating toxic and metabolic risk factors for myopathy, we also sought to determine if severity of illness was associated with development of myopathy. Many OLTx patients develop tachypnea, tachycardia, and elevated WBC count as a result of the extensive transplant procedure or organ rejection, without ever having microbiological evidence of infection. Hence, sepsis was difficult to define in patients who frequently had features that encompass the systemic inflammatory response syndrome4I (SIRS) without ever having evidence of septicemia or a focal infection at the time of transplant. We compared APACHE-I1 scores on the first postoperative day between groups because this value is unlikely to be affected by the presence of myopathy. A score is assigned to various physiologic parameters such as vital signs and serum electrolyte measurements, with higher scores indicating greater severity of illness. This scoring system is predictive of outcome in ICU p a t i e n t~,~~ including OLTx recipie n t~.~~, *~ Affected patients were significantly more ill than control subjects (see table 3), and multivariate analysis revealed a higher index of illness severity that was an independent risk factor for the development of prolonged weakness. Because no patient was known to be bacteremic at the time of the procedure, infection itself was unlikely to contribute to the myopathy that generally occurred within the first week after OLTx. Likewise, the SIRS may be a contributor to development of myopathy, and the presence of SIRS may be reflected in poorer APACHE-I1 scores. Of note, nine patients underwent retransplantation during the study period; all retransplants occurred within 16 days of the first. Of three patients surviving multiple transplants, only one did not develop myopathy .
Patients who developed myopathy were more ill than control subjects on the first postoperative day, and therefore it is difficult to determine how significantly myopathy contributed to the increased duration of ICU hospitalization. However, myopathy probably did influence length of ICU hospitalization because three patients with myopathy depended on mechanical ventilation at some point during the postoperative course with no other obvious nonneuromuscular cause for failure to wean.
Finally, several suggestions may be made regarding the management of transplant patients. In patients with uncontrollable risk factors, such as high APACHE-I1 scores or renal failure, minimizing exposure to CS and NMBAs may be wise. Patients with graft failure who require retransplantation may be candidates for lower doses of IV-CS or alternate immunosuppressive therapies at the time of the second transplant. Also, use of NMBAs that are not hepati-52 NEUROLOGY 50 January 1998 cally metabolized should be considered when additional procedures requiring neuromuscular junction blockade are necessary. Some of these suggestions may be considered in other critically ill patients at risk for myopathy.
